

## Development of a Common Cyclobenzaprine Formulation for Both Encapsulation and Tableting Using StarCap 1500®

N. Do, Ph.D. and T. Farrell, Ph.D. (Colorcon, Inc.)

### OBJECTIVE

To demonstrate the feasibility of using a common formula that can be encapsulated into hard gelatin capsules for clinical trials and subsequently compressed into tablets for commercialization.

### INTRODUCTION

The ability of hard gelatin capsules to blind the contents has made them uniquely suitable for blinding a new drug and its positive comparators in early clinical trials. The trials are usually designed to compare one medication with another to evaluate the relative safety and/or efficacy of the new drug. In those tests, it is a common practice to blind the medications in order to prevent any prejudice from investigators and/or patients.

As compared with other oral dosage forms including hard gelatin capsules, compressed tablets still remain the manufacturers' dosage form of choice for commercialization because of their overall low cost of manufacturing. Furthermore, many coating techniques have been developed to enhance the aesthetic appearance and stability, and mask the taste and odor of the products. In order to eliminate extra steps required for the conversion of clinical capsule formulations to commercial tablet formulations, there is a need of developing a common formula for both capsules and tablets in the early clinical phases.

A low-dose and high-water solubility drug, cyclobenzaprine hydrochloride, was selected for the formulation/process development. A direct blend and encapsulation process was used for the capsules. The tablets were manufactured by direct compression & film-coated with Opadry® II 85F white. Dissolution profiles were generated to compare the *in-vitro* performance of the capsules and film-coated tablets.


### MATERIALS & METHODS

#### Capsule/Tablet Formulation & Process


Ingredient	Percent
Cyclobenzaprine HCl [Vasudha Pharma Chem Ltd]	6.67%
StarCap 1500 [Colorcon]	58.91%
Microcel® 102 [Blanver]	33.67%
Cab-O-Sil® M5-P [Cabot]	0.25%
Magnesium Stearate NF [Mallinckrodt]	0.25%
Opadry II 85F18422 white [Colorcon]	qs

Target capsule fill weight/tablet weight: 150.0mg

With the disintegration properties of StarCap 1500, no additional disintegrants or superdisintegrants were required in the formula.



SEM of Cyclobenzaprine HCl



SEM of StarCap 1500

#### Direct Encapsulation:

Bonapace In-Cap capsule filling machine @ 1500 caps./hr.  
 Hard gelatin capsule shells No. 3, white/white

#### Direct compression:

10-station instrumented Piccola tablet press @ 30rpm  
 9/32" Std. round concave

#### Film-Coating:

20% solid w/w suspension & 3% weight gain  
 15" Thomas Accela Cota coating pan

Inlet Air Temperature: 65°C  
 Exhaust Air Temperature: 45-50°C  
 Tablet Bed Temperature: 45°C  
 Air Flow: 255m<sup>3</sup>/hr (150ft<sup>3</sup>/min)  
 Spray Rate: 8g/min  
 Number of Guns: 1  
 Atomization Air: 1.7 bar (25psi)  
 Pattern Air: 1.7 bar (25psi)  
 Pan Speed: 15rpm

#### Physical Tests

##### Common Final Blend:

Loss-On-Drying (Denver Instrument IR-20  
 Moisture Balance at 105°C)  
 Bulk/Tapped Density (VanKel Tap Density Tester –  
 USP Method I)  
 Dynamic Flow Properties (Sotax FT 300 Flowability Tester)

**Tablets:**

Wgt Variation  
(Erweka Multicheck Tablet Tester)  
Crushing Strength  
(Erweka Multicheck Tablet Tester)  
Friability  
(Vanderkamp Friability Tester)  
Disintegration Time  
(Erweka ZT DT 44 Apparatus)

**Capsules:**

Wgt Variation

The disintegration time of 3-4 minutes required for the dispersion of tablet granules into the dissolution media corresponds to the dissolution time of approximately 3-4 minutes of the hard gelatin capsule shells.

The satisfactory flow properties of the blend were confirmed with the low RSD% in the weight variation test of the capsules and tablets.

**Dissolution Test Method for Capsules & Tablets**

Drug Name/ Dosage Form	USP Apparatus	Speed (RPM)	Medium	Vol. (ml)
Cyclobenzaprine HCl Tablet	I (Basket)	50	0.1N HCl	900

**Weight Variation of Capsules**

Statistics	Filled Caps.	Caps. Fill Wgt
Avg Weight (N=96)	200.9mg	153.2mg
RSD%	2.15	2.82
Min. Weight	192.7mg	145.0mg
Max. Weight	210.1mg	162.4mg
Spread (% of the mean)	± 4.33	± 5.68

**RESULTS & DISCUSSION****Properties of Final Blend**

Test ID	Test Results
Loss-On-Drying	7.95%
Bulk Density	0.48g/cc
Tapped Density	0.65g/cc
Calculated Compressibility Carr's Index	25.4%
Dynamic Flow Properties by Sotax	4.75g/sec
Geometric Mean Diameter	83 microns


**Content Uniformity of Capsules & Tablets**

Statistics	Capsules	Coated Tab.
Avg Potency Assay (N=10)	95.1%	94.7%
Min. Potency Assay	90.8%	93.3%
Max. Potency Assay	100.3%	95.5%
RSD%	2.94	0.74

**Properties of Uncoated Tablets**

Test ID/Statistics	Test Results
Avg Weight (N=55)	149.8mg
RSD%	0.61
Min. Weight	148.0mg
Max. Weight	152.2mg
Spread (% of the mean)	± 1.40
Avg Crushing Strength (N=10)	10.7kp
Friability (N=20)	0.0%
Disintegration Time (N=6)	3min. 24sec. – 3min. 59sec.
Ejection Force	87N
Avg Compression Force	18kN

The variability in content uniformity of the capsules and tablets is consistent with the variability in capsule fill weight and tablet weight. The observation indicates a uniform distribution of the active in the final blend, and the homogeneity was maintained during the encapsulation and compression operation.

**Comparative Dissolution of Cyclobenzaprine HCl Capsules & Tablets 10mg**

*USP 30 – NF 25 Tolerances for cyclobenzaprine HCl tablets — Not less than 75% (Q) of the labeled amount of drug is dissolved in 30 minutes*

With a poorly compactible drug substance such as cyclobenzaprine hydrochloride, the selection of StarCap 1500/MCC combination is suitable to provide not only high tablet hardness & low friability required for film-coating but also a fast disintegration and dissolution rate to the formula.

The cyclobenzaprine hydrochloride tablets and capsules in this study fall into the category of rapidly dissolving products with more than 85% released in 15 minutes or less, and a profile comparison is not necessary.<sup>1</sup>

The dissolution of the Opadry II 85F white coating was fast and did not significantly affect the dissolution rate of the coated tablets.

The dissolution performance of uncoated and coated tablets is similar to that of capsules.

## CONCLUSIONS

The common formula has all the key properties required for the manufacture of hard gelatin capsules and film-coated tablets by a direct blend/encapsulation and direct compression process.

The combination of StarCap 1500/MCC is suitable to provide good compactibility characteristic to the formula and fast disintegration/dissolution to the film-coated tablets.

The satisfactory content uniformity of the capsules and tablets was achieved as a result of the excellent flow properties of the final blend and minimum potential segregation of the active during process.

The *in-vitro* performance of capsules and film-coated tablets has been proven similar with a complete release in the first 15 minutes of the dissolution profiles.

There is a possibility to eliminate the extra steps required to reformulate clinical formulas of hard gelatin capsules into film-coated tablets for commercialization.

## ACKNOWLEDGMENTS

The authors wish to thank David Ferrizzi, Tim Derr, Baldev Rana, Jim Henry, Scott Felix and Jason Hansell for performing all the work in analytical and manufacturing laboratories for this study.

### *Reference:*

<sup>1</sup> Vinod P. Shah, Yi Tson, Pradeep Sathe and Roger L. Williams. Dissolution Profile Comparison Using Similarity Factor, f<sub>2</sub>. *Office of Pharmaceutical Science, Center for Drug Evaluation and Research - Food and Drug Administration, Rockville, MD*

STARCAP 1500<sup>®</sup>, Starch 1500<sup>®</sup> and Colorcon<sup>®</sup> are trademarks of BPSI Holdings LLC.

*AAPS Annual Meeting and Exposition, San Diego, CA, November 13, 2007*

**World Headquarters**

Colorcon

415 Moyer Blvd., PO. Box 24, West Point, PA 19486-0024

Tel: 215-699-7733 Fax: 215-661-2605 Website: [www.colorcon.com/pharma](http://www.colorcon.com/pharma)e-mail: [info@colorcon.com](mailto:info@colorcon.com)

<b>Locations</b>	<b>Telephone</b>	<b>Facsimile</b>	<b>Locations</b>	<b>Telephone</b>	<b>Facsimile</b>
<i>United States</i>			<i>Asia/Pacific</i>		
Santa Ana, California	714-549-0631	714-549-4921	Singapore	65-6438-0318	65-6438-0178
Indianapolis, Indiana	317-545-6211	317-545-6218	Fuji-gun, Shizuoka, Japan	81-5-4465-2711	81-5-4465-2730
Humacao, Puerto Rico	787-852-3815	787-852-0030	Shanghai, China	86-21-5442-2222	86-21-5442-2229
Stoughton, Wisconsin	608-887-8970	608-887-8984	Goa, India	91-832-288-3434	91-832-288-3440
<i>Canada</i>			Seoul, Korea	82-2-2057-2713	82-2-2057-2179
St. Laurent, QC, Canada	514-337-8341	514-337-9159	<i>Latin America</i>		
<i>Europe</i>			Buenos Aires, Argentina	54-11-4552-1565	54-11-4552-3997
Dartford, Kent, England	44-1322-293000	44-1322-627200	Cotia, Brasil	55-11-4612-4262	55-11-4612-3307
Massey, France	33-1-6447-9750	33-1-6932-5983	Bogota, Colombia	571-418-1202	571-418-1257
Idstein, Germany	49-6126-9961-0	49-6126-9961-11	Caracas, Venezuela	58-212-237-9842	58-212-238-2259
Gallarate, Italy	39-0331-776932	39-0331-776831	Santa Fe, México	52-55-3000-5700	52-55-3000-5701 /02
Budapest, Hungary	36-1-200-8000	36-1-200-8010			
Istanbul, Turkey	90-216-465-0360	90-216-465-0361			
Barcelona, Spain	34-9-3589-3756	34-9-3589-3792			

The information contained herein, to the best of our knowledge is true and accurate. Any recommendations or suggestions are made without warranty or guarantee, since the conditions of use are beyond our control. Any information contained herein is intended as a recommendation for use of our products so as not to infringe on any patent.

© 2007 Colorcon, Inc. The information contained in this document is proprietary to Colorcon and may not be used or disseminated inappropriately. STARCAP 1500, Opadry and the Colorcon ellipse are trademarks of BPSI Holdings, LLC.